JMP Securities analyst Jason Butler reiterated a Buy rating on Gamida Cell (GMDA – Research Report) today and set a price target of $15.00. The company’s shares opened today at $1.40.
According to TipRanks, Butler is an analyst with an average return of -9.8% and a 39.54% success rate. Butler covers the Healthcare sector, focusing on stocks such as Cytokinetics, Aquestive Therapeutics, and Prothena.
Gamida Cell has an analyst consensus of Strong Buy, with a price target consensus of $12.40, a 785.71% upside from current levels. In a report released today, Needham also reiterated a Buy rating on the stock with a $8.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $4.72 and a one-year low of $1.47. Currently, Gamida Cell has an average volume of 479.8K.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GMDA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gamida Cell Ltd. is a clinical stage biopharmaceutical company engaging in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Read More on GMDA:
